There is no offer or new partner on the table or else that would be inside information and Gisela would not have purchased shares. However, there is no plan for further share dilution as similarly Gisela would not have executed a share transaction. Gisela expects the stock to go up so obviously in the coming months there are multiple good news points coming. As to partners, you can go to the Exelixis website and see that Exelixis is already partnered with many large pharmas and also with the cancer institute. What is key though is the FDA approval took place and future development and expansion of that is now going to be the norm.